IPO - Profile

Summary

We are a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. We have assembled a world-class team, comprising some of the foremost scientific leaders in the fields of oncology and ACT, including Drs. Rick Klausner, Nick Restifo, Stan Riddell and Crystal Mackall, who have each interrogated and elucidated the mechanisms of T cell biology and its interactions with cancer for decades.

We believe the key to effective cell therapy is the mastery of the identity, fate and function of cells to create More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 25,000,000 Positive High 17.59%

Offering Team

  • Legal counsel
  • Latham & Watkins LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 16 Jun, 2021

Offer 17 Jun, 2021

Look Ahead

Lock Up Expiry Dec 17, 2021

IPO Terms

Offer Price $17.00
Offer Size 25M

Market Sentiments

Stock Price